Akebia Therapeutics Inc. (AKBA): A Case For Going Higher

After Hours

There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

Stocks Info

This NASDAQ-listed company operates within the Biotechnology industry segment, falling under the Healthcare sector. The current market capitalization of Akebia Therapeutics Inc. is $204.82M. A total of 2.84 million shares were traded on the day, compared to an average of 3.31M shares.

In the most recent transaction, Dahan Michel sold 34,840 shares of AKBA for 1.26 per share on May 13 ’24. After the transaction, the SVP, Chief Operating Officer now owns 672,092 company shares. In a previous transaction on May 13 ’24, Hadas Nicole R. sold 12,016 shares at 1.26 per share. AKBA shares that SVP, Chief Legal Officer owns now total 651,243.

Among the insiders who sold shares, Butler John P. disposed of 46,570 shares on Feb 29 ’24 at a per-share price of $1.58. This resulted in the CEO and President holding 2,044,580 shares of AKBA after the transaction. In another insider transaction, Dahan Michel sold 8,661 shares at $1.58 per share on Feb 29 ’24. Company shares held by the SVP, Chief Operating Officer now total 706,932.

Even though price targets are rarely accurate, they do tend to exert some kind of influence from time to time and are often considered important by markets. In terms of 52-week highs and lows, AKBA has a high of $2.48 and a low of $0.78.

Balance Sheet Annually/Quarterly

In a balance sheet, you can see what assets and liabilities the company has, as well as how much equity investors have invested. These figures can be used to calculate a company’s financial ratios to give investors a better idea of its prospects. AKBA’s latest balance sheet shows that the firm has $149.80M in Cash & Short Term Investments as of fiscal 2021. There were $136.05M in debt and $261.05M in liabilities at the time. Its Book Value Per Share was -$0.13, while its Total Shareholder’s Equity was $74.01M.

Analysts Opinion

The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for AKBA is Buy with a score of 5.00.

Most Popular

Related Posts